# Extended-release Pharmacotherapy for Opioid Use Disorder

> **NCT05164549** · PHASE3 · COMPLETED · sponsor: **King's College London** · enrollment: 342 (actual)

## Conditions studied

- Opiate Substitution Treatment

## Interventions

- **DRUG:** Buprenorphine Injectable Product
- **DRUG:** Methadone
- **DRUG:** Buprenorphine

## Key facts

- **NCT ID:** NCT05164549
- **Lead sponsor:** King's College London
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-06
- **Primary completion:** 2022-04-29
- **Final completion:** 2023-03-01
- **Target enrollment:** 342 (ACTUAL)
- **Last updated:** 2024-01-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05164549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05164549, "Extended-release Pharmacotherapy for Opioid Use Disorder". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05164549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*